Abbvie (ABBV) PT Cut to $60 at BMO Capital as Cautious Thesis Materializing Faster

February 4, 2015 1:34 PM

BMO Capital analyst Alex Arfaei lowered his price target on Market Perform-rated Abbvie (NYSE: ABBV) to $60.00 (from $62.00), saying ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found